New Nuwellis CEO McCormick Lays Out Growth Strategy, Eyes Pediatric Market Expansion & FDA Talks
NUWE is trading near its 52-week low of $0.122 (30% below the low).
Summary
Incoming CEO Mike McCormick outlined strategic priorities in a letter to shareholders, effective June 30. He highlighted Q1 2026 revenue growth of 26% and gross margin improvement to 70.1%. Key initiatives include expanding the Aquadex indication for pediatric patients (5kg and above) and engaging with the FDA on a submission strategy. This follows a period of severe financial distress, including a 'going concern' warning, massive dilution, and a recent 1-for-35 reverse stock split to maintain Nasdaq listing. The FDA engagement for Aquadex is a critical step towards broadening market access and improving the company's long-term viability.
At the time of this announcement, NUWE was trading at $0.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6M. The 52-week trading range was $0.12 to $25.95. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.